October 2
A phase 3 trial of Merck and Ridgeback Biotherapeutics’ oral antiviral treatment molnupiravir showed it reduced the risk of hospitalization or death by around 50% in Covid patients.
Merck plans to seek emergency use authorization in the US and submit marketing applications to other global drug regulators.
If authorized by regulatory bodies, molnupiravir c…
Keep reading with a 7-day free trial
Subscribe to Common Sense Daily to keep reading this post and get 7 days of free access to the full post archives.